# A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma

> **NCT00039754** · PHASE1,PHASE2 · TERMINATED · sponsor: **Poniard Pharmaceuticals**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Holmium-166-DOTMP

## Key facts

- **NCT ID:** NCT00039754
- **Lead sponsor:** Poniard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Why stopped:** business reasons
- **Last updated:** 2009-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039754, "A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00039754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*